Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Antipsychotic medications used to treat Alzheimer's patients found lacking

Antipsychotic medications used to treat Alzheimer's patients found lacking

October 12, 2006

Commonly prescribed antipsychotic medications used to treat Alzheimer's patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by the National Institutes of Health's National Institute of Mental Health (NIMH). The trial, known as the Clinical Antipsychotic Trial of Intervention Effectiveness study for Alzheimer's disease (CATIE-AD), was published in the October 12, 2006, issue of the New England Journal of Medicine.

"Antipsychotic medications have been used extensively for Alzheimer's patients without enough solid evidence of whether they are effective," said NIMH Director Thomas R. Insel, M.D. "The study has vital public health implications because it provides physicians and patients with information to more accurately weigh the medications' benefits against their drawbacks, with the needs and unique reactions of their individual patients."




The $16.9 million, five-year trial was conducted at 42 sites and included 421 people. Participants had Alzheimer's-related dementia with additional symptoms such as delusions, aggression, hallucinations, or agitation that were severe enough to disrupt their functioning. The study was aimed at patients who either lived with a family member or caregiver at home, or resided in assisted living facilities, and excluded patients who had already been confined to a nursing home. An essential component of the trial was caregiver participation. He or she provided input to the study doctors on the patient's progress and reactions to the medication.

In this first phase of the trial, patients were randomized to olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal)-all newer antipsychotic medications-or to an inactive pill known as a placebo. Lead author Lon Schneider, M.D., of the University of Southern California Keck School of Medicine and colleagues judged each medication's overall benefits and risks by measuring how long a patient stayed on the medication before discontinuing for any reason. On average, patients discontinued their medication after about eight weeks, regardless of whether they were taking an active medication or placebo, indicating no significant differences in effectiveness between the active medications and placebo.

Some participants did benefit from the treatment; 26 to 32 percent of those taking the active medications improved, compared to 21 percent of those taking placebo. But the antipsychotic medications also were more often associated with troubling side effects, such as sedation, confusion, and weight gain, compared to placebo. Fifteen to 24 percent of those taking active medications discontinued use because of side effects, while only 5 percent of those taking placebo discontinued use citing side effects.

The study investigators determined the medications' effectiveness by balancing their associated benefits with their associated risks. "The antipsychotic medications may be effective against some symptoms in Alzheimer's patients compared to placebo, but their tendency to cause intolerable adverse side effects in this vulnerable population offsets their benefits," concluded Schneider.

Those who discontinued their medications in Phase 1-82 percent-went on to subsequent phases of the CATIE-AD trial in which they were randomized to one of the other study medications that they had not yet taken, or to citalopram, an antidepressant medication. Results of these phases are being analyzed and will be published later.

The flexible design and implementation of the CATIE-AD trial reflects real-world practices, in which newer antipsychotic medications often are used to treat delusions, aggression, hallucinations, and agitation in Alzheimer's patients. Study physicians determined medication dosage levels according to their patients' individual needs, and consulted with the patient and caregivers when determining if and when a patient should discontinue. Patients represented a broad range of ages (average age was 80 years), diversity, level of disability and cognitive difficulties.

"In many cases, the moderate to severe thinking and behavioral symptoms of Alzheimer's precipitate placement in a nursing home, at which point the economic and social costs associated with Alzheimer's care skyrocket," said co-lead author Pierre Tariot, M.D., of the Banner Alzheimer's Institute in Phoenix, AZ. "By identifying the limitations of existing treatment options, this study is an important step toward finding a treatment that can delay full-time nursing home confinements, and reduce the suffering of patients and their families."

NIH/National Institute of Mental Health



Related Antipsychotic Medication Current Events and Antipsychotic Medication News Articles Antipsychotic Medication Current Events and Antipsychotic Medication News RSS Antipsychotic Medication Current Events and Antipsychotic Medication News RSS
Early and network-oriented care may help adolescents at risk of developing psychosis
Family and network oriented, stress-reducing care improves level of overall functioning and mental health in adolescents at risk of developing psychosis, suggests a recent Finnish study.

Innappropriate drug prescriptions wasting millions, raising health risks
A recent study in Oregon suggests that drugs designed for treating the most severe mental illnesses are often prescribed at inappropriately low doses and at considerable expense, for use in conditions where their benefit has not been established.

Antipsychotic drugs double risk of death among Alzheimer's patients
New research into the effects of antipsychotic drugs commonly prescribed to Alzheimer's patients concludes that the medication nearly doubles risk of death over three years.

Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.

Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.

Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Restrictive drug policies often cause schizophrenic patients to discontinue medication
Policies requiring authorization before physicians can prescribe newer medications to schizophrenic patients may be counter-productive. According to a new study, patients in Maine's Medicaid program who found themselves in this situation were 29% more likely to stop or disrupt medication use than patients not subject to the policy.

Weight gain induced by antipsychotic drugs can be avoided
A research team from Université Laval's Faculty of Medicine and Robert-Giffard Hospital has demonstrated that weight gain induced by the use of antipsychotic drugs-which in extreme cases can be as high as 30 kilos in only one month-can be avoided through a specially designed weight control program.

Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs
Lifestyle intervention and the drug metformin are both effective against antipsychotic-induced weight gain, and treatment is most effective when the two therapies are combined, according to a study in the January 9/16 issue of JAMA.

Blood pressure drug curbs brain damage from PTSD
A drug used to treat high blood pressure and enlargement of the prostate may protect the brain from damage caused by post-traumatic stress disorder, Alzheimer's disease, depression and schizophrenia.
More Antipsychotic Medication Current Events and Antipsychotic Medication News Articles
The Evidence-based Guide to Antipsychotic Medications

The Evidence-based Guide to Antipsychotic Medications
by Anthony J. Rothschild (Editor)

"The Evidence-Based Guide to Antipsychotic Medications" is designed to provide both clinicians and residents with focused, comprehensive, and clinically relevant information regarding the use of antipsychotic medications to treat a broad range of psychiatric conditions - from mood and anxiety disorders to substance abuse, personality disorders, and schizophrenia. The volume editor is a renowned psychiatrist and author with more than 25 years of experience in both clinical and research settings diagnosing and treating patients with mood and psychotic disorders. In addition, each of the volume's 13 contributors is an expert with many years of clinical experience to draw on. The book is down-to-earth and reader-friendly and is structured for maximal utility in both coverage and format: Key...

The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need T

The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need T
Lafcadio (Primary Contributor)



Dosing Antipsychotic Medications: Insights From Data and Practice - A Video Symposium

Dosing Antipsychotic Medications: Insights From Data and Practice - A Video Symposium
Also With: William Glazer M.D. (Primary Contributor), Peter J. Weiden M.D. (Primary Contributor), Dan L. Zimbroff M.D. (Primary Contributor)

Dosing is often the key to establishing efficacy and minimizing side effects of atypical antipsychotics. Tailoring medication dose to severity of illness and phase of illness allows clinicians to meet individual patient needs. Clinical experience regarding dosing may differ from data collected during clinical trials. The PsychLink experts will merge the insights gleaned from clinical trials with the lessons learned from clinical practice to outline optimal dosing strategies of atypical antipsychotics.

Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)

Neurotransmitter Receptors in Actions of Antipsychotic Medications (Handbooks in Pharmacology and Toxicology)
by Michael S. Lidow (Editor)

Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have fewer extrapyramidal side effects, are less sedating, and attempt to address the negative symptoms of schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications presents a glimpse into the development of these breakthroughs and the field's current status in one definitive volume.The exhaustive chapters cover the basic knowledge of schizophrenic syndromes and provide a general description of available antipsychotic drugs....

Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians.

Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians.
by Ronald J. Diamond (Author), Ruth Ross (Author), Patricia L. Scheifler (Author), Peter J. Weiden (Author), Ronald I. Diamond (Author)

From the National Alliance for the Mentally Ill, this book gives consumers, their families, and clinicians information about antipsychotics that have recently become available. For people with schizophrenia and other psychotic disorders, antipsychotic medications are the key to recovery. Yet older medications have serious side effects and rarely affect symptoms like lethargy. New antipsychotics have advantages, but they are not for everyone, if only because of their cost. This book helps consumers and their families weigh the pros and cons of switching medications and guides them through the process of switching. For clinicians, it includes technical details on the new medications and their side effects.

  Atypical Antipsychotic Medications in Dementia, etc.
by George T., ed. Grossberg (Author)



Maudsley Antipsychotic Medication Review Service Guidelines: Establishing a Medication Review System for Atypical Antipsychotic Patients

Maudsley Antipsychotic Medication Review Service Guidelines: Establishing a Medication Review System for Atypical Antipsychotic Patients
by Ruth Ohlsen (Author), Shubulade Smith (Author), David Taylor (Author), Lyn Pilowsky (Author)

This is the definitive guide to best antipsychotic prescribing practice today. Informed prescribing and best practice relies not only on clinical experience and expertise, but on up to date knowledge of all the currently available antipsychotic medication, and an understanding of the neurobiology and neuropharmacology involved in the process and treatment of psychoses.
Navigating the vast database covering antipsychotic psychopharmacology is a daunting task, leaving many clinicians overwhelmed, confused and tending to "fall back" on older prescribing methods because of the lack of readily available information about newer, more suitable alternatives.
Clinicians can now turn to this authoritative work, which will provide a truly practical "how to" guide to antipsychotic prescribing....

Sharing decisions in consultations involving anti-psychotic medication: A qualitative study of psychiatrists' experiences [An article from: Social Science & Medicine]

Sharing decisions in consultations involving anti-psychotic medication: A qualitative study of psychiatrists' experiences [An article from: Social Science & Medicine]
by C. Seale (Author), R. Chaplin (Author), P. Lelliott (Author), A. Quirk (Author)

This digital document is a journal article from Social Science & Medicine, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
In psychiatry, and in treating people with a diagnosis of schizophrenia in particular, there are obstacles to achieving concordant, shared decision making and in building a co-operative therapeutic alliance where mutual honesty is the norm. Studies of people with a diagnosis of schizophrenia have revealed critical views of medical authority, particularly over the issue of enforced compliance with antipsychotic medication. Psychiatrists are known to place particular value on such medication. This qualitative...

  Primer for prescription medications: the first long-acting atypical antipsychotic.(RX Primer): An article from: Annals of the American Psychotherapy Association
by Harpriya A. Bhagar (Author), Alan D. Schmetzer (Author)

This digital document is an article from Annals of the American Psychotherapy Association, published by Thomson Gale on December 22, 2005. The length of the article is 1381 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Primer for prescription medications: the first long-acting atypical antipsychotic.(RX Primer)
Author: Harpriya A. Bhagar
Publication: Annals of the American Psychotherapy Association (Magazine/Journal)
Date: December 22, 2005
Publisher: Thomson Gale
Volume: 8 Issue: 4 Page: 28(1)

Distributed by Thomson...

The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need Them

The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need Them
Lafcadio (Primary Contributor)



© 2009 BrightSurf.com